SUNNYVALE, Calif., July 5, 2011 /PRNewswire/ -- Today, Molecular Devices, a leading provider of instruments, software, and consumables for drug discovery and life sciences research, announced that the Drug Discovery Division of Genetix will join Molecular Devices.
With the addition of Genetix, Molecular Devices continues to grow as a leading technology supply company for research, biotechnology, and pharmaceutical customers around the world.
Research in Pharma/Biotech is shifting toward biotherapeutic drugs (antibodies, proteins, and vaccines). Two key products from Genetix, the ClonePix™ and QPix™ instrument platforms, address cell lines used in biotherapeutic research. ClonePix is an automated mammalian cell selection platform that significantly expedites the process of identifying and selecting cells that produce biotherapeutic candidates, reducing both time and cost.
In addition, the CloneSelect™ Imager and CellReporter from Genetix will extend Molecular Devices' imaging portfolio. These products offer a good value for a budget conscious end user.
Commenting on the move, Mark Verheyden, President of Molecular Devices said, "We are excited about welcoming Genetix into the Molecular Devices team, knowing that the combined business will be better positioned to serve our customers."
About Molecular Devices, Inc.
At Molecular Devices we have one focus—our customers. Whether a long-time user, recent adopter, or prospective customer, your needs fuel our actions. We hire creative, best-in-class people to design, manufacture, and commercialize analytical instruments, software, and assays as well as provide dedicated follow-on support. Understanding your laboratory workflow is our top priority, and we direct product development toward solvin
|SOURCE Molecular Devices Inc.|
Copyright©2010 PR Newswire.
All rights reserved